Viral syncytia evolve to resist interferon

3 min read Original article ↗

Acknowledgements

We thank Zene Matsuda at the Institute of Medical Science (University of Tokyo) for providing dual split protein system: DSP 1-7 and DSP 8-11, and Chhing-Wen Chang (University of Massachusetts Chan Medical School) for providing A549plusC3 cell line, Sarah Anzick (RTB, NIAID) for NSG support, Bernard Lafont, Johnson Reed, and Nicole Lackemeyer (NIAID SARS-CoV-2 Virology Core BSL-3 facility), for superb support, training, and assistance. The contributions of the NIH authors were made as part of their official duties as NIH federal employees, are in compliance with agency policy requirements, and are considered works of the U.S. government. However, the findings and conclusions presented in this paper are those of the authors and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.

Funding

J.W.Y. discloses the research of this work is supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) [grant ZIAAI001320]. All other authors declare no relevant funding.

Author information

Authors and Affiliations

  1. Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, USA

    Tiansheng Li  (李天胜), Zhe Hu  (胡哲), James Gibbs, Ivan Kosik, Jaroslav Holly & Jonathan W. Yewdell

  2. Laboratory of Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA

    Insung Kang, Martina Kosikova, Zhiping Ye & Hang Xie

  3. Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA

    Juan Ye  (叶娟)

  4. Texas Biomedical Research Institute, San Antonio, TX, USA

    Chengjin Ye & Luis Martinez-Sobrido

  5. Microscopy and Imaging Core Facility, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA

    Kazuyo Takeda

  6. HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute (NCI), NIH, Frederick, MD, USA

    Guoli Shi  (史国利) & Alex A. Compton

  7. SARS-CoV-2 Virology Core Laboratory, Division of Intramural Research, National Institutes of Health, Bethesda, MD, USA

    Reed F. Johnson

Authors

  1. Tiansheng Li  (李天胜)
  2. Insung Kang
  3. Juan Ye  (叶娟)
  4. Zhe Hu  (胡哲)
  5. James Gibbs
  6. Chengjin Ye
  7. Kazuyo Takeda
  8. Ivan Kosik
  9. Guoli Shi  (史国利)
  10. Jaroslav Holly
  11. Martina Kosikova
  12. Zhiping Ye
  13. Alex A. Compton
  14. Luis Martinez-Sobrido
  15. Reed F. Johnson
  16. Hang Xie
  17. Jonathan W. Yewdell

Corresponding authors

Correspondence to Tiansheng Li  (李天胜) or Jonathan W. Yewdell.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Source data

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, T., Kang, I., Ye, J. et al. Viral syncytia evolve to resist interferon. Nat Commun (2026). https://doi.org/10.1038/s41467-026-74676-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41467-026-74676-8